Very low valuation of $65 million ,well financed with $20 million and BIG milestones is aorund the corner with the Phase 3 readout of the Covid 19 program and potential approval of the drug in Canada. They expect to submit 2 NDA´s during the year including the covid 19 treatment . This under radar stock has potential to run to $10 and even higher .STRONG BUY Market Cap $65 million Cash $20 million Price $1.03 Presentation https://7343a5f0-1b48-4477-8577-969...d/3d295b_2468d721a70a45c0bfaf03f68b748c4c.pdf Adding to the COVID-19 treatment toolbox https://www.thechronicleherald.ca/m...ing-to-the-covid-19-treatment-toolbox-540087/ APLIF: Phase 3 PRESECO Trial Readout in Late March 2021… https://finance.yahoo.com/news/aplif-phase-3-preseco-trial-130500968.html
(APLIF) $0.64 --Covid Drug Phase 3 readout now confirmed for THIS quarter ..Positive results could push this undiscovered stock toward 10 dollars .GL New Presentation https://3d295b82-6395-4c9f-ac2e-e8b...d/3d295b_b13c9780e6bd4cecad42757f254a078f.pdf APLIF: DSMB Recommends for PRESECO Trial to Complete; Data Expected in 3Q21… https://finance.yahoo.com/news/aplif-dsmb-recommends-preseco-trial-121800846.html
